1. Home
  2. TENX vs CSBR Comparison

TENX vs CSBR Comparison

Compare TENX & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.72

Market Cap

74.1M

Sector

Health Care

ML Signal

N/A

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$4.91

Market Cap

65.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
CSBR
Founded
1967
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.1M
65.4M
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
TENX
CSBR
Price
$1.72
$4.91
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $9.63
N/A
AVG Volume (30 Days)
★ 2.0M
8.9K
Earning Date
11-11-2026
12-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $2,900,000.00
Revenue This Year
N/A
$9.83
Revenue Next Year
N/A
$8.50
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$4.59
52 Week High
$19.40
$8.31

Technical Indicators

Market Signals
Indicator
TENX
CSBR
Relative Strength Index (RSI) 42.67 47.05
Support Level $1.34 $4.71
Resistance Level $2.00 $6.29
Average True Range (ATR) 0.12 0.17
MACD 0.09 0.01
Stochastic Oscillator 70.91 36.54

Price Performance

Historical Comparison
TENX
CSBR

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Share on Social Networks: